



\$163

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q63893

Zvia AGUR, et al.

Appln. No.: 09/827,229

Group Art Unit: 1631

Confirmation No.: 7712

Examiner: Marjorie A. MORAN

Filed: April 6, 2001

For: **SYSTEM AND METHODS FOR OPTIMIZED DRUG DELIVERY AND
PROGRESSION OF DISEASED AND NORMAL CELLS**

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

Copies of the listed references can be found in parent application no. 09/691,053. If that is not the case, please advise and the undersigned attorney will attempt to obtain copies and provide them to the Examiner.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R. § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of


RECEIVED
JUL 16 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 09/827,229

Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore a check for the fee of \$180.00 under 37 C.F.R. § 1.17(p) is attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Chidambaram Subramanian
Registration No. 43,355

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: July 8, 2003

<p>Substitute for Form 1449 A & B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p><i>JUL 08 2003</i></p> <p><i>PATENT & TRADES</i></p>				<i>RECEIVED PATENT & TRADES JUL 16 2003 USPTO CENTRAL FILE CENTER 16012800</i>	
				<i>Complete if Known</i>	
				Application Number	09/827,229
				Confirmation Number	7712
				Filing Date	April 6, 2001
				First Named Inventor	Zvia AGUR
				Art Unit	1631
				Examiner Name	Marjorie A. MORAN
Sheet 1		of 4	Attorney Docket Number Q63893		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		R. Stoffel et al., "Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets," The American Society of Hematology, Blood, vol. 87, no. 2, pp. 567-573, January 15, 1996.	
		Warren S. Alexander, "Thrombopoietin and the c-Mpl receptor: insights from gene targeting," The International Journal of Biochemistry & Cell Biology, pp. 1027-1035, January 28, 1999.	
		M. Miyazaki, et al., "The Relationship Between Carboplatin AUC and Serum Thrombopoietin Kinetics in Patients with Lung Cancer," 2 nd Department of Internal Medicine, Hiroshima University School of Medicine, Anti Cancer Research, vol. 19, pp. 667-670 (1999).	
		S. Vadhan-Raj, et al., "Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer," Annals of Internal Medicine, vol. 126, no. 9, pp. 673-681, May 1997.	
		H. -E. Wichmann, et al., "A Mathematical Model of Thrombopoiesis in Rats," Cell Tissue Kinet, vol. 12, pp. 551-567, January 1979.	
		L. A. Harker, et al., "Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers," The American Society of Hematology, Blood, vol. 95, no. 8, pp. 2514-2522, April 15, 2000.	
		H. Mayani, et al., "Lineage Commitment in Human Hemopoiesis Involves Asymmetric Cell Division of Multipotent Progenitors and Does not Appeal to be Influenced by Cytokines," Journal of Cellular Physiology, vol. 157, pp. 579-586, 1993.	
		David W. Golde, "The Stem Cell," Scientific American, pp. 36-43, December 1991.	
		S. J. Morrison, et al., "The Biology of Hematopoietic Stem Cells," Annu. Rev. Cell Dev. Biol., vol. 11, pp. 35-71, 1995.	
		J. Eller, et al., "Modelling Thrombopoiesis Regulation-I; Model Description and Simulation Results," Comput. Math. Applic., vol. 14, no. 9-12, pp. 841-848, 1987.	
		G. K. von Schulthess, et al., "Oscillating platelet counts in healthy individuals: Experimental investigation and quantitative evaluation of thrombocytopoietic feedback control," Scand J Haematol, vol. 36, pp. 473-479, March 8, 1986.	
		L. A. Harker, et al., "Dose-Response Effects of Pegylated Human Megakaryocyte Growth and Development Factor on Platelet Production and Function in Nonhuman Primates," The American Society of Hematology, Blood, vol. 88, no. 2, pp. 511-521, July 15, 1996.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO

JUL 08 2003

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number 09/827,229

Confirmation Number 7712

Filing Date April 06, 2001

First Named Inventor Zvia AGUR

Art Unit 1631

Examiner Name Marjorie A. MORAN

Attorney Docket Number Q63893

RECEIVED
TECH CENTER 1600
JUL 10 2003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		P. A. Fielder, "Regulation of Thrombopoietin Levels by c-mpl-Mediated Binding to Platelets," The American Society of Hematology, Blood, vol. 87, no. 6, pp. 2154-2161, March 15, 1996.	
		John E. J. Raski, et al., "Molecules in focus; The thrombopoietic factor, Mpl-ligand," The International Journal of Biochemistry & Cell Biology, vol. 30, pp. 657-660, 1998.	
		F. J. de Sauvage, et al., "Physiological Regulation of Early and Late Stages of Megakaryocytopoiesis by Thrombopoietin," Departments of Molecular Biology, Cell Genetics, vol. 183, pp. 651-656, February 1996.	
		F. Tacke, et al., "Endogenous serum levels of thrombopoietic cytokines in healthy whole-blood and platelet donors: implications for plateletpheresis," British Journal of Haematology, vol. 105, pp. 511-513, 1999.	
		S. A. Burstein, et al., "Megakaryopoiesis and platelet formation," Williams Hematology, 5 th ed., Ch. 118, McGraw-Hill, Inc., 1995.	
		R. Schofield, et al., "Self-Maintenance Capacity of CFU-S," Journal of Cellular Physiology, vol. 103, pp. 355-362, 1980.	
		M. Rosendaal, et al., "Organization of Haemopoietic Stem Cells: The Generation-Age Hypothesis," Cell Tissue Kinet., vol. 12, pp. 17-29, 1979.	
		A. Iliadis, et al., "Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model," Computers and Biomedical Research, vol. 33, pp. 211-226, 2000.	
		F. L. Pereira, et al., "A new optimization based approach to experimental combination chemotherapy," Frontiers Med. Biol. Engng., vol. 6, no. 4, pp. 257-268, 1995.	
		*Hassin Agur, "Optimizing Chemotherapy Scheduling Using Search Heuristics," pp. 2-36	
		Kenji Terashi, et al., "Close Association between Clearance of Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF) and G-CSF Receptor on Neutrophils in Cancer Patients," Antimicrobial Agents and Chemotherapy, vol. 43, no. 1, pp. 21-24, January 1999.	
		T. H. Price, et al., "Effect of Recombinant Granulocyte Colony-Stimulating Factor on Neutrophil Kinetics in Normal Young and Elderly Humans," The American Society of Hematology, vol. 88, no. 1, pp. 335-340, July 1, 1996.	
		B. I. Lord, et al., "The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 9499-9503, December 1989.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/827,229	
				Confirmation Number	7712	
				Filing Date	April 6, 2001	
				First Named Inventor	Zvia AGUR	
				Art Unit	1631	
				Examiner Name	Marjorie A. MORRIS	
Sheet		3	of	4	Attorney Docket Number	Q63893

RECEIVED
PATENT CENTER
JUL 08 2003
180012300

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		J. Y. Mary, "Normal Human Granulopoiesis Revisited. I. Blood Data," Biomedicine & Pharmacotherapy, vol. 38, pp. 33-43, 1984.	
		J. Y. Mary, "Normal Human Granulopoiesis Revisited. II. Bone Marrow Data," Biomedicine & Pharmacotherapy, vol. 38, pp. 66-77, 1984.	
		C. Dresch, et al., "Growth fraction of myelocytes in normal human granulopoiesis," Cell Tissue Kinet. vol. 19, pp. 11-22, 1986.	
		S. Schmitz, et al., "The effect of continuous G-CSF application in human cyclic neutropenia: a model analysis," British Journal of Haematology, vol. 90, pp. 41-47, 1995.	
		S. Schmitz, et al., "Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis," International Society for Experimental Hematology, Experimental Hematology, vol. 21, pp. 755-760, 1993.	
		L. A. Harker, et al., "Regulation of Platelet Production and Function by Megakaryocyte Growth and Development Factor in Nonhuman Primates," The American Society of Hematology, no. 5, pp. 1833-1844, March 1996.	
		Warren S. Alexander, "Thrombopoietin," The Walter and Eliza Hall Inst. for Medical Research, Growth Factors, vol. 17, pp. 13-24, 1999.	
		Kenneth Kaushansky, "Thrombopoietin: The Primary Regulator of Platelet Production," The Journal of The American Society of Hematology, Blood, vol. 86, no. 2, pp. 419-431, July 15, 1995.	
		Saroj Vadhan-Raj, "Recombinant Human Thrombopoietin: Clinical Experience and In Vivo Biology," Seminars in Hematology, vol. 35, No. 3, pp. 261-268, July 1998.	
		Laurence A. Harker, "Physiology and clinical applications of platelet growth factors," Curr Opin Hematol, vol. 6, pp. 127-134, 1999.	
		Jack Levin, "Thrombopoietin -- Clinically Realized?," The New England Journal of Medicine, vol. 336, no. 6, pp. 1-3, February 6, 1997.	
		G. Somlo, et al., "Recombinant Human Thrombopoietin in Combination with Granulocyte Colony-Stimulating Factor . . . High-Dose Chemotherapy," The American Society of Hematology, Blood, vol. 93, no. 9, pp. 2798-2806, May 1, 1999.	
		K. J. Neelis, et al., "The Efficacy of Single-Dose Administration of Thrombopoietin with Coadministration . . . Myelosuppressed Rhesus Monkeys," The American Society of Hematology, Blood, vol. 90, no. 7, pp. 2565-2573, October 1, 1997.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

<p style="text-align: center;">Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i></p>				<i>Complete if Known</i>	
				Application Number	09/827,229
				Confirmation Number	7712
				Filing Date	April 06, 2001
				First Named Inventor	Zvia AGUR
				Art Unit	1631
				Examiner Name	Marjorie A. MORAN
Sheet	4	of	4	Attorney Docket Number	Q63893

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JUL 08 2003
ENTERED 10012003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		L. J. Murray, et al., "Thrombopoietin Mobilizes Cd34+ Cell Subsets Into Peripheral Blood And Expands Multilineage Progenitors In Bone Marrow Of Cancer Patients With Normal Hematopoiesis," Experimental Hematology, vol. 26, pp. 207-216, 1998.	
		R. L. Basser, et al., "Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor with Filgrastim after Dose-Intensive Chemotherapy in Patients with Advanced Cancer," The American Society of Hematology, Blood, Vol. 89, no. 9, pp. 3118-3128, 1997.	
		D. Zucker-Franklin, "The Ultrastructure of Megakaryocytes and Platelets," Dept. of Medicine and Rheumatic Diseases Study Group, New York, The Platelets, Ch. 55, pp. 1553-1629.	
		L. A. Harker, et al., "Thrombokinetics in Man," The Journal of Clinical Investigation, vol. 48, pp. 963-974, 1969.	
		Laurence H. Harker, "Thrombokinetics in Idiopathic Thrombocytopenic Purpura," British Journal of Haematology, pp. 95-104, 1970.	
		R. Sungaran, et al., "Localization and Regulation of Thrombopoietin mRNA Expression in Human Kidney, Liver, Bone Marrow, and Spleen Using in Situ Hybridization," The American Society of Hematology, Blood, vol. 89, no. 1, pp. 101-107, 1997.	
		Y. Nagata, et al., "Serum Thrombopoietin Level is not Regulated by Transcription but by the Total Counts of both Megakaryocytes and Platelets during Thrombocytopenia and Thrombocytosis," Tsukuba Life Science Center, Thrombosis and Haemostasis, vol. 77, pp. 808-814, 1997.	
		H. Nagahisa, et al., "Bone Marrow Stromal Cells Produce Thrombopoietin and Stimulate Megakaryocyte Growth and Maturation but Suppress Proplatelet Formation," The American Society of Hematology, Blood, vol. 87, no. 4, pp. 1309-1316, February 15, 1996.	
		I. Athanassios, et al., "Comparison Between Optimata's Claims and Contemporary, 'state of the art' in Optimizing of Anticancer Chemotherapy," Computers and Biomedical Research, vol. 33, pp. 211-226, 2000.	
		Hui-Chi Hsu, et al., "Circulating Levels of Thrombopoietic and Inflammatory Cytokines in Patients with Clonal and Reactive Thrombocytosis," J Lab Clin Med, vol. 134, no. 4, pp. 392-397, 1999.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.